Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02606422
Other study ID # NA_00071337
Secondary ID R01DC014475
Status Completed
Phase N/A
First received
Last updated
Start date April 2013
Est. completion date August 11, 2023

Study information

Verified date April 2024
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of high definition transcranial direct current stimulation (HD-tDCS) during language therapy in PPA participants over time. Anodal HD-tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with HD-tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of HD-tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs.


Description:

A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on their residual language and cognitive skills: a) writing to dictation b) oral spelling c) oral and written naming of pictures d) word-picture matching f) written and oral picture description g) digit span h) spatial span i) verbal learning j) grammatical sentence production k) oral word repetition l) sentence comprehension Quality of Life questionnaires: Participants will be administered standardized and non-standardized quality-of-life questionnaires before, after, and at follow-up intervals of each experimental period. The purpose of these questionnaires is to assess whether the proposed interventions have affected participants' well-being and the general quality of their life. B. Spoken and Written Word Production Therapy Interventions Individuals with PPA will receive spoken and written word production intervention tailored to their degree of deficit. Two interventions (basic and advanced) will be implemented, treating the main lexical retrieval deficits in PPA, in oral and written modalities. The goal of the combined interventions is to promote interaction between phonological and orthographic representations and processes in the remediation of lexical retrieval deficits that are prominent in all PPA subtypes. C. Assessment of Language Therapy Tasks: Follow-up assessment will probe all sets of trained phoneme-grapheme correspondences, words, or other stimuli (e.g. sentences) to identify whether or not the patient has retained knowledge of the trained items. Differences in baseline measures in pre- and post-therapy accuracy for phoneme-grapheme correspondences for each patient will be evaluated using the following: percentages of total number of points correct, arithmetic differences between percentage scores, and permutation tests (Pearson's chi-square test; Fisher's exact test). C. HD-tDCS Methods: Participants will take part in 10-15 consecutive training sessions (3-5 per week), separated by 2 months. Anodal HD-tDCS has typically been shown to up-regulate neuronal excitability and produce enhancement of behavioral performance. A Soterix-CT device will be delivering current at an intensity of 1-2 milliamps(mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) for a maximum of 20 minutes in the HD-tDCS groups and for a maximum of 30 seconds in the Sham group. For both interventions (HD-tDCS and Sham) the electrical current will be increased in a ramp-like fashion at the onset of the stimulation eliciting a transient tingling sensation on the scalp that usually disappears over seconds. D. Imaging Methods: Imaging will be performed at the beginning of enrollment, before and after each 12-to-15-day HD-tDCS treatment, and at follow-up intervals for up to 8 time points per individual on a 3T Philips system, and will consist of resting-state fMRI (rsfMRI), MPRAGE, and diffusion tensor imaging (DTI). Each scanning session will last approximately 1 hour. E. Statistical Analyses: In the within-subject crossover protocol, each participant will be administered three experimental conditions: Control (natural progression), IFG HD-tDCS+language (henceforth abbr. HD-tDCS treatment (word production) and sham HD-tDCS+language (henceforth abbr. sham treatment). To achieve an accurate estimate of degeneration and rate of decline in each participant at their particular stage of the disease progression, each participant will first be enrolled in the control condition (natural progression), such that for the first 12 weeks they will not receive any therapy. Then the participant will receive either the HD-tDCS treatment followed by sham, or vice versa. All analyses, behavioral and imaging, will be under the oversight of the study statisticians. F. Study duration and number of study visits required of research participants. Before any intervention, participants will be enrolled in a control condition for 12 weeks during which no therapy will be provided to enable us to assess their personal decline rate. After this period they will be randomly assigned to either sham or HD-tDCS experimental conditions. After 1-3 weeks of HD-tDCS application (3-5 sessions in a week, 10-15 sessions per stimulation site) there will be an interval of approximately 2 months and then we will implement the other two HD-tDCS conditions in a within-subject cross-over design. Participants will be followed up at 2-week and 2-month follow-up intervals. G. Blinding, including justification for blinding or not blinding the trial, if applicable. Participants will be blinded to the application of anodal or sham HD-tDCS. To achieve blinding, all participants will be fitted with the HD-tDCS electrodes placed over the left inferior frontal gyrus. The Soterix-CT device will be used for double-blinding purposes. H. Justification of why participants will not receive routine care or will have current therapy stopped Participation in this study will not disrupt any current care or therapy. I. Justification for inclusion of a placebo or non-treatment group All participants will undergo active and sham conditions, thus serving as their own control. J. Definition of treatment failure or participant removal criteria Participants will be removed from the study if they are unable to comply with task instructions or tolerate the HD-tDCS procedure. K. Description of what happens to participants receiving therapy when the study ends or if a participant's participation in the study ends prematurely When the study ends participants will continue to receive management with their neurologist as usual. If a patient's participation in the study ends prematurely s/he will still receive care as before. In sum, termination of the study or termination of participation in it will not affect the regular therapy he or she may be receiving. L. Qualification of investigators: The PI and co-investigators have extensive research and clinical experience with all study tasks: behavioral language therapy (including spelling, naming, and repetition therapy. The investigators have already published a tDCS study on the behavioral results for the improvement of spelling abilities.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date August 11, 2023
Est. primary completion date July 12, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria: - Must be clinically diagnosed with semantic variant PPA (svPPA), non-fluent variant PPA (nfvPPA), or logopenic variant PPA (lvPPA), unclassifiable PPA, or MCI. Diagnosis will be based on neuropsychological testing, language testing (most commonly the Western Aphasia Battery), MRI and clinical assessment. - Must be right-handed. - Must be speakers of English. - Must have at least 9th grade education. Exclusion Criteria: - Uncorrected visual or hearing impairment by self report. - Stroke/other premorbid neurological disorder affecting the brain. - Any other language-based learning disorder other than PPA. - Inability to follow directions for baseline tasks. - Western Aphasia Battery Aphasia Quotient (AQ) <30 (indicating severe language impairment). Exclusion Criteria for MRI Participation: - Severe claustrophobia. - Cardiac pacemakers or ferromagnetic implants. - Pregnant women.

Study Design


Intervention

Device:
Active HD-tDCS plus Speech-Language Therapy
Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
Sham plus Speech-Language Therapy
Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins University National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Tippett DC, Hillis AE, Tsapkini K. Treatment of Primary Progressive Aphasia. Curr Treat Options Neurol. 2015 Aug;17(8):362. doi: 10.1007/s11940-015-0362-5. — View Citation

Tsapkini K, Frangakis C, Gomez Y, Davis C, Hillis AE. Augmentation of spelling therapy with transcranial direct current stimulation in primary progressive aphasia: Preliminary results and challenges. Aphasiology. 2014;28(8-9):1112-1130. doi: 10.1080/02687 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in oral naming (trained items) We will investigate any changes in performance from pre- to post-treatment levels of change in % accuracy in trained items. 35 weeks
Primary Change in written naming (trained items) We will investigate any changes in performance from pre- to post-treatment levels of change in % accuracy in trained items. 35 weeks
Primary Change in oral naming (untrained items) We will investigate any changes in performance from pre- to post-treatment levels of change in % accuracy in untrained items. 35 weeks
Primary Change in written naming (untrained items) We will investigate any changes in performance from pre- to post-treatment levels of change in % accuracy in untrained items. 35 weeks
Secondary Change in other language and cognitive task performances (global cognitive changes) Secondary outcome variables will be generalization of the improvement induced by the stimulation of the IFG in other language and cognitive functions with the same neural substrates. 35 weeks
Secondary Changes in functional connectivity Using rsfMRI, DTI, and volumetric imaging, we will investigate whether tDCS intervention will result in different changes in connectivity between the targeted area and other nodes in the "language network," also controlling for the effect of gray and white matter volume loss as covariates. 35 weeks
See also
  Status Clinical Trial Phase
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT04957537 - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia N/A
Completed NCT04045990 - Network Modulation in Alzheimer's Disease N/A
Recruiting NCT05443633 - Enhancing Language Function in Aphasia N/A
Completed NCT05860647 - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia N/A
Recruiting NCT03887481 - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA N/A
Completed NCT03728582 - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Completed NCT02541097 - Preventing Language Decline in Dementia N/A
Recruiting NCT00537004 - Language in Primary Progressive Aphasia
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Active, not recruiting NCT05742698 - Nabilone for Agitation in Frontotemporal Dementia Phase 2
Completed NCT02439853 - Communication Bridge Speech Therapy Research Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Completed NCT04726527 - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Completed NCT05537688 - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed NCT05525377 - Better Living With Non-memory-led Dementia N/A
Completed NCT02928848 - Transcranial Direct Current Stimulation for Primary Progressive Aphasia N/A
Completed NCT04939818 - Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

External Links